Chau Khuong, MPH

Chau Q. Khuong is a Partner at OrbiMed, a healthcare dedicated investment firm with approximately $12 billion AUM. Chau focuses on venture capital activities and has invested in novel drugs and therapeutic devices across a broad range of disease areas from oncology to infectious diseases to ophthalmology. Prior to OrbiMed, he developed skills in start-up operations and business development at Veritas Medicine, Inc. and in basic immunology research at the Yale School of Medicine and Massachusetts General Hospital. He serves or has served as a Board representative for drug and medical device development companies such as Arius (acquired by Roche), Glaukos (NYSE: GKOS), Graybug Vision, Inspire MedSystems (NYSE: INSP), Intercept Pharma (NASDAQ: ICPT), NextCure, Pieris Pharmaceuticals (NASDAQ: PIRS), Rempex Pharmaceuticals (acquired by Medicines Co.), ReViral Ltd, Sonendo, and Synlogic (NASDAQ: SYBX). Chau holds a B.S. in molecular, cellular and developmental biology and M.P.H. with concentration in infectious disease, both from Yale University.